Flerie
Flerie's portfolio company Nanologica has received an important order from a new customer
Stockholm, 24 April, 2025. Flerie AB's (publ) portfolio company Nanologica has announced that the company has secured an order for its silica-based purification media NLAB Saga® from a new customer in China.
The order for NLAB Saga® amounts to USD 180,000 and is expected to be delivered in the second quarter. The customer is a large pharmaceutical manufacturer and the order is for the evaluation of NLAB Saga® at production scale for use in the production of GLP-1 analogs, a rapidly growing area globally for the treatment of type 2 diabetes and obesity.
"This is very good news for Nanologica and an important step into the rapidly growing and strategically important GLP-1 segment. We look forward to following the company's continued development in China." says Mark Quick, Partner at Flerie.
Read Nanologica's full press release here: nanologica-ab-receives-order-worth-usd-180-000-from-new-customer-in-china.pdf
Flerie's holding in Nanologica amounts to 43%.
For more information:
Mark Quick
Email: ir@flerie.com
| Datum | 2025-04-24, kl 10:15 |
| Källa | MFN |
Investera som eToros bästa investerare! Med eToros CopyTrader™, kan du automatiskt kopiera andra investerares beslut. Hitta investerare som du tror på och kopiera deras investeringar i realtid. Inga extra avgifter tas ut för funktionen.